Evidence map›Paper›PMID 39911826›Full record

ArticleFrontiers in pharmacology2024

Yanqiu Zheng, Huibiao Li, Shiyu Qi, Fan Xiao, Jinbin Song, Shiyin Liu, Xinlin Chen, Yanwu Li, Muyuan Chen

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yanqiu Zheng *The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Huibiao Li *The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Shiyu Qi *The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Fan XiaoScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jinbin SongScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Shiyin LiuSchool of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xinlin ChenSchool of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yanwu LiScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Muyuan ChenThe First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: The efficacy of PAE was evaluated using a DSS-induced UC mice model and the colon inflammation and mucosal barrier were comprehensively assessed. Furthermore, Network pharmacological analysis was utilized to identify potential targets and signaling pathways of PAE in the UC treatment. The proportion and the markers of Th17 and Treg cells in the spleen and colon were examined. The signal transduction was detected Results: PAE mitigated colon inflammation and intestinal barrier damage in UC mice. Network pharmacological analysis showed that the targets of UC intervention by PAE may be closely related to Th17 cell differentiation, the IL-17 signaling pathway, and cytokine-cytokine receptor interaction. Mechanistically, PAE regulated the balance of Th17/Treg and inhibited the Notch1/Math1 pathway in the colon of UC mice. Conclusion: PAE could alleviate colon inflammation and mucosal barrier damage in UC, which are related to the inhibition of Notch1 and the regulation of the Th17/Treg balance. PAE might be a potential candidate agent for UC treatment.

Indexed as

colonic mucosaNotch1Periplaneta americana extractTh17/Tregulcerative colitis

Identifiers

PMID39911826
PMCPMC11794537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.